Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGaA Cetuximab European Filing To Include 330 Colorectal Patients

Executive Summary

Merck KGaA's European licensing application for cetuximab (ImClone's Erbitux) will include 330 colorectal cancer patients

You may also be interested in...



Merck KGaA Moves 2d EGFR Agent Into Full Development; Erbitux On Track

Merck KGaA is moving the fully humanized epidermal growth factor receptor blocking antibody EMD-72000 into Phase II studies this year

Merck KGaA Moves 2d EGFR Agent Into Full Development; Erbitux On Track

Merck KGaA is moving the fully humanized epidermal growth factor receptor blocking antibody EMD-72000 into Phase II studies this year

Bristol/ImClone Erbitux BLA Timeline Depends On Merck KGaA Phase II Study

ImClone's timeline for refiling its Erbitux BLA hinges on completion of Merck KGaA's Phase II study in colorectal cancer patients

Related Content

UsernamePublicRestriction

Register

PS039747

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel